Vidya Perera

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 14

Top Venues

Scientific reports

CPT: pharmacometrics & systems pharmacology

British journal of clinical pharmacology

Clinical pharmacokinetics

University of Sydney (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Sydney Mar 01 2008 - Dec 01 2011

Australia

PHD :: Pharmacy

University of Sydney Mar 08 2003 - Dec 11 2007

Australia

BSC :: Pharmacology

Publications

Samira M Garonzik, David H Salinger, Maria Palmisano, Amy J Sehnert, Neelima Thanneer, Hyunmoon Back, Julie D Seroogy, Daniel D Gretler, Amit Roy, Vidya Perera
Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy. CPT: pharmacometrics & systems pharmacology (2024)
Peter Chang, Vidya Perera, David H Salinger, Samira M Garonzik, Neelima Thanneer, Hyunmoon Back, Julie D Seroogy, Daniel D Gretler, Amy J Sehnert, Maria Palmisano, Amit Roy
Characterization of mavacamten pharmacokinetics in patients with hypertrophic cardiomyopathy to inform dose titration. CPT: pharmacometrics & systems pharmacology (2024)
Manting Chiang, Caroline Sychterz, Vidya Perera, Samira Merali, Maria Palmisano, Ian E Templeton, Lu Gaohua
Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype. Clinical pharmacology and therapeutics (2023)
Vidya Perera, Grigor Abelian, Danshi Li, Zhaoqing Wang, Liping Zhang, Susan Lubin, Wei Chen, Akintunde Bello, Bindu Murthy
Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants. Clinical pharmacokinetics 61 (6) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports 12 (1) (2022)
Vidya Perera, Grigor Abelian, Danshi Li, Zhaoqing Wang, Liping Zhang, Susan Lubin, Akintunde Bello, Bindu Murthy
Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment. Clinical pharmacokinetics 61 (10) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports 12 (1) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports 12 (1) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Takayo Ueno, Tomomi Shiozaki, Wei Chen, Xiaohui Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants. Scientific reports 12 (1) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports 12 (1) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor. Scientific reports 12 (1) (2022)
Vidya Perera, Zhaoqing Wang, Susan Lubin, Lisa J Christopher, Wei Chen, Sophia Xu, Dietmar Seiffert, Mary DeSouza, Bindu Murthy
Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa Inhibitor. Cardiology and therapy 11 (3) (2022)
Thomas M Polasek, Geoffrey T Tucker, Michael J Sorich, Michael D Wiese, Titus Mohan, Amin Rostami-Hodjegan, Porntipa Korprasertthaworn, Vidya Perera, Andrew Rowland
Prediction of olanzapine exposure in individual patients using physiologically based pharmacokinetic modelling and simulation. British journal of clinical pharmacology 84 (3) (2018)
Vidya Perera, Joseph M Luettgen, Zhaoqing Wang, Charles E Frost, Cynthia Yones, Cesare Russo, John Lee, Yue Zhao, Frank P LaCreta, Xuewen Ma, Robert M Knabb, Dietmar Seiffert, Mary DeSouza, Pierre Mugnier, Brenda Cirincione, Takayo Ueno, Robert J A Frost
First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects. British journal of clinical pharmacology 84 (5) (2018)

Vidya Perera.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Vidya Perera